Menu
Back to User profile » Prof. Dr. Alessandro Vatrella
Papers published by Prof. Dr. Alessandro Vatrella:
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Pelaia C, Giacalone A, Ippolito G, Pastore D, Maglio A, Piazzetta GL, Lobello N, Lombardo N, Vatrella A, Pelaia G
Pragmatic and Observational Research 2024, 15:45-51
Published Date: 11 March 2024
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
Pelaia C, Ferrante Bannera A, Rotundo FL, Tropea FG, Armentaro G, Maglio A, Sciacqua A, Vatrella A, Pelaia G
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:995-1002
Published Date: 26 May 2023
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G
Journal of Asthma and Allergy 2021, 14:1165-1172
Published Date: 24 September 2021
Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R, Pelaia G
Drug Design, Development and Therapy 2021, 15:1275-1284
Published Date: 23 March 2021
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
Pelaia C, Crimi C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, Ciotta Jnr D, D'Amato M, Macchia L, Nolasco S, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Spadaro G, Valenti G, Vatrella A, Crimi N
Journal of Asthma and Allergy 2021, 14:163-173
Published Date: 22 February 2021
Early management of COPD: where are we now and where do we go from here? A Delphi consensus project
Di Marco F, Balbo P, de Blasio F, Cardaci V, Crimi N, Girbino G, Pelaia G, Pirina P, Roversi P, Santus P, Scichilone N, Vatrella A, Pasqualetti P, Carone M
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:353-360
Published Date: 4 February 2019
Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients
Ricciardi L, Dal Col J, Casolari P, Memoli D, Conti V, Vatrella A, Vonakis BM, Papi A, Caramori G, Stellato C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3173-3190
Published Date: 12 October 2018
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G
Drug Design, Development and Therapy 2018, 12:619-628
Published Date: 21 March 2018
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
Drug Design, Development and Therapy 2017, 11:3137-3144
Published Date: 30 October 2017
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R
Therapeutics and Clinical Risk Management 2016, 12:1075-1082
Published Date: 1 July 2016
Fractional exhaled nitric oxide-measuring devices: technology update
Maniscalco M, Vitale C, Vatrella A, Molino A, Bianco A, Mazzarella G
Medical Devices: Evidence and Research 2016, 9:151-160
Published Date: 23 June 2016
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R
Therapeutics and Clinical Risk Management 2015, 11:1563-1572
Published Date: 8 October 2015
Dupilumab: a novel treatment for asthma
Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G
Journal of Asthma and Allergy 2014, 7:123-130
Published Date: 4 September 2014